Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer

Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer

287778

Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common and difficult-to-treat form of eye cancer — the company announced in a press release. The breakthrough therapy status was awarded after a Phase 3 trial showed that tebentafusp worked better than currently available treatments in extending survival in certain newly diagnosed uveal melanoma patients. This designation is given to…

You must be logged in to read/download the full post.